Vol 9, No 1 (February 08, 2018): Journal of Gastrointestinal Oncology (Evolving Role of Immune-oncology Therapeutics in GI Malignancies)

Original Article

A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
Annika L. Windon, Arturo Loaiza-Bonilla, Christopher E. Jensen, Michael Randall, Jennifer J. D. Morrissette, Stuti G. Shroff
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:1-10
.
 (08 February 2018) 
PDF Full Text (8154) Open Access Get Permission
Advanced age does not increase morbidity in pancreaticoduodenectomy
Guilherme Naccache Namur, Anna Carolina Batista Dantas, Ricardo Jureidini, Thiago Costa Ribeiro, Ulysses Ribeiro Junior, Estela Figueira, Ivan Cecconello, Telesforo Bacchella
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:11-16
.
 (08 February 2018) 
PDF Full Text (3404) Open Access Get Permission
Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy
Andrew E. Hendifar, Jonathan I. Chang, Brian Z. Huang, Richard Tuli, Bechien U. Wu
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:17-23
.
 (08 February 2018) 
PDF Full Text (8381) Open Access Get Permission
Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy
William H. Jin, Eric A. Mellon, Jessica M. Frakes, Gilbert Z. Murimwa, Pamela J. Hodul, Jose M. Pimiento, Mokenge P. Malafa, Sarah E. Hoffe
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:24-34
.
 (08 February 2018) 
PDF Full Text (4869) Open Access Get Permission
Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study
Brice Jabo, Matthew J. Selleck, John W. Morgan, Sharon S. Lum, Khaled A. Bahjri, Mayada Aljehani, Carlos A. Garberoglio, Mark E. Reeves, Jukes P. Namm, Naveenraj L. Solomon, Fabrizio Luca, Crickett Dyke, Maheswari Senthil
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:35-45
.
 (08 February 2018) 
PDF Full Text (4703) Open Access Get Permission
Evaluation of altered expression of miR-9 and miR-106a as an early diagnostic approach in gastric cancer
Khadije Shirmohammadi, Sareh Sohrabi, Zahra Jafarzadeh Samani, Hosein Effatpanah, Reza Yadegarazari, Massoud Saidijam
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:46-51
.
 (08 February 2018) 
PDF Full Text (3678) Open Access Get Permission
Establishment and validation of prognostic nomograms in first- line metastatic gastric cancer patients
Yukiya Narita, Shigenori Kadowaki, Isao Oze, Yosuke Kito, Takeshi Kawakami, Nozomu Machida, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Seiji Ito, Masahiro Tajika, Yasushi Yatabe, Hirofumi Yasui, Kei Muro
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:52-63
.
 (08 February 2018) 
PDF Full Text (4563) Open Access Get Permission
Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country
Eugenia Cordero-García, Allan Ramos-Esquivel, Warner Alpízar-Alpízar
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:64-72
.
 (08 February 2018) 
PDF Full Text (3851) Open Access Get Permission
Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer
Smit Singla, Emmanuel Gabriel, Raed Alnaji, William Du, Kristopher Attwood, Hector Nava, Steven N. Hochwald, Moshim Kukar
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:73-79
.
 (08 February 2018) 
PDF Full Text (3394) Open Access Get Permission
Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base
Waqar Haque, Vivek Verma, E. Brian Butler, Bin S. Teh
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:80-89
.
 (08 February 2018) 
PDF Full Text (4322) Open Access Get Permission
Colorectal lymphoma in Mexico: clinico-pathological and survival analysis
Everardo Jaime- Andrade, Leonardo S. Lino- Silva, Rosa A. Salcedo- Hernández, César Zepeda- Najar
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:90-95
.
 (08 February 2018) 
PDF Full Text (3286) Open Access Get Permission
Age-related rates of colorectal cancer and the factors associated with overall survival
Emmanuel Gabriel, Kristopher Attwood, Eisar Al-Sukhni, Deborah Erwin, Patrick Boland, Steven Nurkin
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:96-110
.
 (08 February 2018) 
PDF Full Text (5388) Open Access Get Permission
Investigation of targetable predictive and prognostic markers in gallbladder carcinoma
Azfar Neyaz, Nuzhat Husain, Sameer Gupta, Swati Kumari, Aditi Arora, Namrata Puneet Awasthi, Kiran Preet Malhotra, Sanjeev Misra
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:111-125
.
 (08 February 2018) 
PDF Full Text (6428) Open Access Get Permission
Disparities in resection of hepatic metastases in colon cancer
Madalyn G. Neuwirth, Andrew J. Epstein, Giorgos C. Karakousis, Ronac Mamtani, E. Carter Paulson
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:126-134
.
 (08 February 2018) 
PDF Full Text (4451) Open Access Get Permission

Short Communication

The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
Sofia Palacio, Peter J. Hosein, Isildinha Reis, Ikechukwu I. Akunyili, Vinicius Ernani, Terri Pollack, Jessica Macintyre, Maria H. Restrepo, Jaime R. Merchan, Caio M. Rocha Lima
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:135-139
.
 (08 February 2018) 
PDF Full Text (3947) Open Access Get Permission

Editorial on Evolving Role of Immune-oncology Therapeutics in GI Malignancies1

The coming of age: immunotherapy in gastrointestinal malignancies
Devalingam Mahalingam
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:140-142
.
 (08 February 2018) 
PDF Full Text (3270) Open Access Get Permission

Review Article on Evolving Role of Immune-oncology Therapeutics in GI Malignancies1

Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response
Ari Rosenberg, Devalingam Mahalingam
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:143-159
.
 (08 February 2018) 
PDF Full Text (9478) Open Access Get Permission
Updates on immunotherapy for colorectal cancer
Aparna Kalyan, Sheetal Kircher, Hiral Shah, Mary Mulcahy, Al Benson
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:160-169
.
 (08 February 2018) 
PDF Full Text (9207) Open Access Get Permission
Immunotherapy in colorectal cancer: for the select few or all?
Sukeshi Patel Arora, Devalingam Mahalingam
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:170-179
.
 (08 February 2018) 
PDF Full Text (9829) Open Access Get Permission
How does the tumor microenvironment play a role in hepatobiliary tumors?
Fathima Kamil, Julie H. Rowe
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:180-195
.
 (08 February 2018) 
PDF Full Text (7139) Open Access Get Permission
Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers
Nischala Ammannagari, Ajlan Atasoy
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:196-207
.
 (08 February 2018) 
PDF Full Text (6371) Open Access Get Permission
Immunomodulation in hepatocellular cancer
Sunyoung Lee, Matthew Loecher, Renuka Iyer
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:208-219
.
 (08 February 2018) 
PDF Full Text (7669) Open Access Get Permission

Perspective on Evolving Role of Immune-oncology Therapeutics in GI Malignancies1

Approach and management of checkpoint inhibitor-related immune hepatitis
Aravind Sanjeevaiah, Thomas Kerr, Muhammad Shaalan Beg
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:220-224
.
 (08 February 2018) 
PDF Full Text (5218) Open Access Get Permission
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers
Muhammad Shaalan Beg, Jeffrey Meyer
Journal of Gastrointestinal Oncology  
2018;
9
(1)
:225-230
.
 (08 February 2018) 
PDF Full Text (3610) Open Access Get Permission

Disclosure:

1. The series “Evolving Role of Immune-oncology Therapeutics in GI Malignancies” was commissioned by the Editorial office, Journal of Gastrointestinal Oncology without any sponsorship or funding. Devalingam Mahalingam served as the unpaid Guest Editor for the series.